[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100644280":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":30,"centralContacts":34,"locations":40,"responsibleParty":65,"collaborators":68,"id":92,"slug":93,"hasResults":94,"nctId":95,"briefTitle":96,"officialTitle":97,"acronym":98,"eligibilityCriteria":99,"healthyVolunteers":94,"sex":100,"minAge":101,"maxAge":25,"enrollmentInfo":102,"targetDuration":25,"studyType":105,"phases":106,"briefSummary":108,"conditions":109,"keywords":111,"overallStatus":114,"whyStopped":25,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":124},{"fullName":5,"class":6},"Hospital Clinic of Barcelona","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"sFlt-1\u002FPlGF ratio-based management algorithm","EXPERIMENTAL","In the intervention arm, participants will be managed according to a predefined algorithm based on the sFlt-1\u002FPlGF ratio, which will guide the timing of delivery according to established thresholds and gestational age.",[13],"Other: sFlt-1\u002FPlGF ratio-guided management algorithm",{"label":15,"type":16,"description":17,"interventionNames":18},"Standard care","ACTIVE_COMPARATOR","The control arm will receive usual care for severe preeclampsia according to each center's clinical protocols.",[19],"Other: Usual Care",[21,26],{"type":6,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"sFlt-1\u002FPlGF ratio-guided management algorithm","Management will be optimized based on angiogenic factor results. The sFlt-1\u002FPlGF ratio will be determined at 30.0 weeks or at diagnosis between 30.0 and 33.6 weeks of gestation, and weekly measurements will be repeated. Based on predefined thresholds, delivery will be planned as follows: if sFlt-1\u002FPlGF \\>655, planned delivery will occur after fetal lung maturation if gestational age is \\\u003C35 weeks; if sFlt-1\u002FPlGF \\\u003C655 and ≥110, planned delivery will occur after 34 weeks (with prior lung maturation if gestational age is \\\u003C35 weeks); and if sFlt-1\u002FPlGF \\\u003C110, planned delivery will occur at 37 weeks. If immediate delivery criteria are met, delivery will be recommended regardless of the ratio.",[9],null,{"type":6,"name":27,"description":28,"armGroupLabels":29,"otherNames":25},"Usual Care","The control arm will receive usual care for severe preeclampsia according to each center's clinical protocols. The sFlt-1\u002FPIGF ratio will be determined at 30 weeks or diagnosis between 30 and 33.6 weeks of gestation, and weekly measurements will be repeated, but the ratio will not be available to the clinician or researchers",[15],[31],{"name":32,"affiliation":5,"role":33},"Francesc Figueras Retuerta, PhD","PRINCIPAL_INVESTIGATOR",[35],{"name":36,"role":37,"phone":38,"phoneExt":25,"email":39},"Cesar Gil Armas, MD","CONTACT","+34 638298597","gil3@recerca.clinic.cat",[41],{"facility":42,"status":25,"city":43,"state":43,"zip":44,"country":45,"countryCode":46,"cosmosGeoPoint":47,"geoPoint":52,"contacts":53},"c\u002F Sabino Arana, 1. 08028 Barcelona","Barcelona","08028","Spain","ES",{"type":48,"coordinates":49},"Point",[50,51],2.15899,41.38879,{"lat":51,"lon":50},[54,57,60,61,63],{"name":55,"role":37,"phone":56,"phoneExt":25,"email":39},"Cesar David Gil Armas, MD","638298597",{"name":32,"role":37,"phone":58,"phoneExt":25,"email":59},"+34649835994","ffiguera@clinic.cat",{"name":32,"role":33,"phone":25,"phoneExt":25,"email":25},{"name":62,"role":33,"phone":25,"phoneExt":25,"email":25},"Anna Peguero Yus, PhD",{"name":36,"role":64,"phone":25,"phoneExt":25,"email":25},"SUB_INVESTIGATOR",{"type":33,"investigatorFullName":66,"investigatorTitle":67,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"Francesc Figueras","Head of Fetal-Maternal Medicine",[69,72,74,76,78,80,82,84,86,88,90],{"name":70,"class":71},"Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, Barcelona, Spain.","UNKNOWN",{"name":73,"class":71},"Instituto de investigación Hospital 12 de Octubre",{"name":75,"class":6},"Hospital de Sant Pau",{"name":77,"class":6},"Fundació Sant Joan de Déu",{"name":79,"class":6},"Hospital Universitario La Paz",{"name":81,"class":71},"Hospital Materno-Infantil de Canarias. Las Palmas de Gran Canaria. Spain",{"name":83,"class":6},"Hospital Son Llatzer",{"name":85,"class":6},"Hospital Clinico Universitario San Cecilio",{"name":87,"class":6},"Hospital Universitario Virgen de la Arrixaca",{"name":89,"class":6},"Fundacion Para La Investigacion Hospital La Fe",{"name":91,"class":6},"Hospital Vall d'Hebron","100644280","algorithm-based-timing-of-delivery-using-the-sflt-1plgf-ratio-in-early-onset-severe-preeclampsia-map-2-study--management-based-on-angiogenic-markers-in-preeclampsia-2-study--100644280",false,"NCT07665112","Algorithm-Based Timing of Delivery Using the sFlt-1\u002FPlGF Ratio in Early-Onset Severe Preeclampsia. (MAP 2 Study : Management Based on Angiogenic Markers in Preeclampsia 2 Study )","Multicenter Randomized Trial of an sFlt-1\u002FPlGF Ratio-Based Algorithm for Timing of Delivery in Early-Onset Severe Preeclampsia: The MAP 2 Study","MAP 2","Inclusion criteria :\n\n* Women aged 18 or older\n* Singleton pregnancies\n* Diagnosed with severe preeclampsia per 2020 ACOG criteria, between 30.0 and 33.6 weeks by first-trimester ultrasound.\n\nExclusion criteria :\n\n* Major fetal malformations\n* Confirmed genetic syndromes.","FEMALE","18 Years",{"count":103,"type":104},386,"ESTIMATED","INTERVENTIONAL",[107],"NA","Preeclampsia is a serious pregnancy complication caused by abnormal placental development and function. It can lead to high blood pressure and damage to organs such as the liver, kidneys, brain, or cardiovascular system. In these cases, the only definitive treatment is delivery. However, deciding when to deliver is challenging: delaying delivery increases risks for both mother and baby, while delivering too early increases complications related to prematurity.\n\nThis study aims to evaluate whether a blood test measuring the sFlt-1\u002FPlGF ratio an angiogenic marker that reflects placental function and predicts complications more accurately than traditional clinical criteria can help determine the optimal timing of delivery in women with severe preeclampsia between 30 weeks and 33 weeks plus 6 days of gestation. It is a multicenter, randomized controlled clinical trial conducted in 11 referral hospitals in Spain and will include 386 singleton pregnancies.\n\nParticipants will be randomly assigned to one of two groups. In the control group, standard expectant management will be followed, aiming to continue the pregnancy until 34 weeks if maternal and fetal conditions remain stable, and the sFlt-1\u002FPlGF results will be masked. In the study group, delivery timing will be guided by the sFlt-1\u002FPlGF ratio: if the ratio is greater than 655, delivery will be planned from 30 weeks onward; if greater than 110, delivery will be planned from 34 weeks; and if 110 or lower, pregnancy may continue until 37 weeks.\n\nThe study has two primary outcomes. The first is a composite of severe maternal complications, including neurological, hepatic, renal, respiratory, or cardiovascular dysfunction, severe hypertension, placental abruption, or fetal death. The second is a composite of neonatal complications, including admission to the neonatal intensive care unit or neonatal death.\n\nThe goal is to demonstrate that using angiogenic markers reduces maternal complications without significantly increasing neonatal complications. If successful, this approach could support more individualized management of early-onset severe preeclampsia, improving maternal safety while carefully balancing the risks of prematurity for the newborn.",[110],"Severe Preeclampsia",[112,113],"Angiogenic biomarkers","sFlt-1\u002FPlGF ratio","NOT_YET_RECRUITING","2026-06-18",{"date":117,"type":118},"2026-06-24","ACTUAL",{"date":120,"type":104},"2026-07-01",{"date":122,"type":104},"2029-12-31",{"name":5,"class":6},1]